Compare TC & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TC | FEMY |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.0M | 34.3M |
| IPO Year | 2018 | 2021 |
| Metric | TC | FEMY |
|---|---|---|
| Price | $7.57 | $0.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.83 |
| AVG Volume (30 Days) | 14.4K | ★ 1.5M |
| Earning Date | 12-16-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,115,721.00 | $2,061,502.00 |
| Revenue This Year | N/A | $64.02 |
| Revenue Next Year | N/A | $147.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 63.53 |
| 52 Week Low | $6.50 | $0.31 |
| 52 Week High | $39.00 | $1.80 |
| Indicator | TC | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 25.13 | 39.60 |
| Support Level | $6.70 | $0.58 |
| Resistance Level | $7.94 | $0.66 |
| Average True Range (ATR) | 1.10 | 0.07 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 14.67 | 23.93 |
Token Cat Ltd is an omnichannel automotive marketplace in China. The company operates in one segment, providing auto shows, special promotion event services, virtual dealerships, online marketing services, and more. It organizes auto shows to facilitate transactions between consumers and auto dealers, which include auto dealers, automakers, and automotive service providers. It offers services through its online platform and offline events.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.